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Introduction
============

Rheumatoid arthritis has been shown to be associated with substantial cardiovascular comorbidity, but most of the available evidence originates from studies on the risk of myocardial infarction and cardiovascular mortality.[@ref1] [@ref2] [@ref3] In contrast to the risk of myocardial infarction related to rheumatoid arthritis, the results from studies on risk of stroke have been inconsistent, which may reflect the diverse causes of stroke, including atherothrombosis, thromboembolism, and haemorrhage, but also differences in study designs and characteristics of rheumatoid arthritis populations examined.[@ref2] [@ref3] [@ref4] [@ref5] [@ref6] [@ref7] [@ref8] [@ref9] [@ref10] Atrial fibrillation is an important and modifiable risk factor for stroke.[@ref11] To our knowledge, however, studies on the incidence of atrial fibrillation, and its effect on the risk of stroke, in patients with rheumatoid arthritis have not been reported, even though the incidence of atrial fibrillation is known to be increased by several factors that are more prevalent in people with rheumatoid arthritis, such as heart failure, ischaemic heart disease, and smoking.[@ref4] [@ref12] [@ref13] [@ref14] Furthermore, studies have suggested that inflammation plays a role in the development of atrial fibrillation.[@ref15] In this study, therefore, we examined the risk of atrial fibrillation and stroke associated with rheumatoid arthritis in a Danish nationwide register based cohort study from 1997 to 2009.

Methods
=======

Study cohort and data sources
-----------------------------

Our study cohort consisted of all Danish inhabitants aged over 15 years on 1 January 1997, as identified through the Danish civil registration system. In Denmark, all people are issued with a unique and permanent personal identifier at birth, which enabled data from several individual level Danish nationwide registers to be combined. Data on morbidity came from the national patient register, where diagnoses from all hospital admissions (from 1978) and outpatient activities (from 1995) are listed according to the ICD-8 (international classification of diseases, 8th revision) codes until 1994 and ICD-10 thereafter. Here, dates and institutions providing each patient contact are recorded along with one primary and, if appropriate, one or more secondary diagnoses. All prescriptions dispensed from Danish pharmacies have been registered since 1995 in the Danish register of medicinal product statistics, which we used to obtain information on drug treatment at an individual level, including the anatomical therapeutic chemical class, drug strength, quantity, and date of dispensed prescription. Information on income and migration were available through Statistics Denmark. All the registers used have nationwide coverage; as reporting of data is obligatory and linked to financial reimbursements, they are effectively complete.[@ref16] [@ref17]

Cohort entry and follow-up
--------------------------

We followed the cohort from baseline in 1997 until occurrence of a study end point, emigration, or death or 31 December 2009, whichever came first. We excluded people with a diagnosis of rheumatoid arthritis, atrial fibrillation, or stroke before baseline from the study cohort. We monitored cohort participants for the development of rheumatoid arthritis as determined by ICD-10 codes M05-M06 in combination with a dispensed prescription of disease modifying antirheumatic drugs within one year before or after the time of diagnosis (see web appendix for anatomical therapeutic chemical codes used). This method has previously been validated with both sensitivity and specificity of greater than 80%.[@ref18] We used the last of either the prescription date or the date of diagnosis as the starting point for the time at risk with rheumatoid arthritis.

End points and potential endpoint predictors
--------------------------------------------

We detected cases of atrial fibrillation by admissions with the ICD code I48 (ICD-10) and stroke by admissions with I60, I61, I63, and I64 (ICD-10). Both end points have been validated in the Danish patient registry previously.[@ref19] [@ref20] [@ref21] [@ref22]

At study baseline on 1 January 1997, we characterised all cohort participants with regard to potential endpoint predictors. On the basis of dispensed prescriptions during 1996, we established baseline cardiovascular drug use, as well as the presence of diabetes by the use of glucose lowering drugs, as previously done.[@ref23] We identified hyperthyroid disease by dispensed antithyroid drugs. We defined hypertension as the concurrent use of at least two antihypertensive agents.[@ref24] We established the presence of heart failure, ischaemic heart disease, heart surgery, valvular disease, cardiomyopathy, and chronic obstructive pulmonary disease by occurrence of respective ICD codes before baseline. Details of anatomical therapeutic chemical and ICD codes used in the above definitions are listed in the web appendix.

To have a non-inflammatory rheumatic disease as a comparator to rheumatoid arthritis and to evaluate the potential influence of surveillance bias, we also identified participants who received a primary diagnosis of osteoarthritis (ICD-10: M15-19, M47). We calculated an index of socioeconomic status from 1 to 5 on the basis of participants' income in the years 1992-6 standardised by age.

For both end points, we did supplementary analyses in which we matched each patient with rheumatoid arthritis with four controls with same sex and year of birth. We then determined the characteristics described above in each set of matched participants at the index date of the patient with rheumatoid arthritis.

Statistical analysis
--------------------

To obtain an accurate allocation of exposure time, people who developed rheumatoid arthritis contributed with time at risk in the reference group until the rheumatoid arthritis index date; that is, outcomes before the index date would be allocated to the reference group. We calculated overall as well as sex and age specific absolute incidence rates (IR) of atrial fibrillation and stroke. We calculated sex and age specific attributable risk with rheumatoid arthritis as exposure (IR~rheumatoid\ arthritis~−IR~general\ population~/IR~rheumatoid\ arthritis~). We fitted multivariable Poisson regression models to estimate incidence rates ratios for atrial fibrillation and stroke in patients with rheumatoid arthritis with the general population as reference. We also analysed the risk of atrial fibrillation and stroke including sex, age, calendar year, and socioeconomic index as covariates by proportional hazard regression models (Cox regression), which yielded identical risk estimates to those from Poisson regression. However, we preferred Poisson regression models because detailed analyses using Cox regression were unfeasible owing to the large size of the study dataset. As analyses showed interaction between age and rheumatoid arthritis status in models evaluating stroke risk, and to assess potential effects of difference in sex distribution, we present both overall and age/sex stratified regression models. In addition to the follow-up time, we used age divided into five year intervals (overall model) and calendar year (overall and age stratified models) as time scales. In the matched design study, we estimated risk as hazard ratios from Cox regression analyses with the matched groups considered as individual strata. We tested proportional hazards assumptions and found them to be valid.

We report continuous variables as means with standard deviations and categorical data as frequencies and percentages, unless otherwise indicated. We considered a two tailed P value less than 0.05 to be significant and provide 95% confidence intervals. We used SAS version 9.2 for data management and Stata version 11.1 for statistical analysis. The study was conducted and reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations.[@ref25]

Results
=======

From the total Danish population, 4 282 752 people were eligible to enter the study cohort. Figure 1[](#fig1){ref-type="fig"} shows a flow chart of the study population, and table 1[](#tbl1){ref-type="table"} shows baseline characteristics of people who developed rheumatoid arthritis and the general population. A total of 18 247 people were identified as having rheumatoid arthritis, with a female predominance of approximately 70%, a mean age at disease onset of 59.2 (SD 14.1) years and a median follow-up of 4.8 (interquartile range 2.3-8.1) years. During follow-up, 165 343 people, including 718 with rheumatoid arthritis, had a stroke and 156 484 people, including 774 with rheumatoid arthritis, were diagnosed as having atrial fibrillation. This corresponded to incidence rates of both end points that were significantly higher in patients with rheumatoid arthritis than in the general population, regardless of strata based on sex or age (table 2[](#tbl2){ref-type="table"}). Figures 2[](#fig2){ref-type="fig"} and 3[](#fig3){ref-type="fig"} illustrate the relations between age and rates of atrial fibrillation and stroke in more detail.

![**Fig 1** Flow chart of study population](linj003076.f1_default){#fig1}

###### 

 Baseline characteristics. Values are numbers (percentages) unless stated otherwise

  Characteristic                           General population (n=4 164 088)   Rheumatoid arthritis (n=18 247)
  ---------------------------------------- ---------------------------------- ---------------------------------
  Female sex                               2 121 459 (50.9)                   12 726 (69.7)
  Mean (SD) age (years):                   45.6 (18.4)                        52.4 (14.9)
   Women                                   46.8 (19.2)                        52.0 (15.2)
   Men                                     44.3 (17.6)                        53.2 (14.0)
  Comorbidity:                                                                
   Hypertension                            148 893 (3.6)                      936 (5.1)
   Heart failure                           27 221 (0.7)                       101 (0.6)
   Ischaemic heart disease                 109 382 (2.6)                      620 (3.4)
   Hyperthyroid disease                    16 945 (0.4)                       136 (0.7)
   Chronic obstructive pulmonary disease   49 666 (1.2)                       270 (1.5)
   Heart surgery                           16 363 (0.4)                       101 (0.6)
   Diabetes                                71 288 (1.7)                       368 (2.0)
  Mean (SD) socioeconomic index            3.00 (1.41)                        2.77 (1.39)
  Cardiovascular drugs:                                                       
   β blocker                               150 322 (3.6)                      942 (5.2)
   Cholesterol lowering drug               28 587 (0.7)                       174 (1.0)
   ACEI/ARB                                119 704 (2.9)                      740 (4.1)
   Calcium channel blocker                 93 711 (2.3)                       592 (3.2)
   Thiazide diuretic                       176 078 (4.2)                      1 161 (6.4)
   Loop diuretic                           130 861 (3.1)                      695 (3.8)
   Spironolactone                          15 170 (0.4)                       68 (0.4)
   Vitamin K antagonist                    14 259 (0.3)                       98 (0.5)
   Platelet inhibitor                      155 122 (3.7)                      794 (4.4)

ACEI=angiotensin converting enzyme inhibitor; ARB=angiotensin 2 receptor blocker.

###### 

 Atrial fibrillation and stroke: numbers of events, time at risk, and risk estimates in general population and patients with rheumatoid arthritis

                            General population            Rheumatoid arthritis   Attributable risk\* (%)   Incidence rate ratio† (95% CI)                      
  ------------------------- -------------------- -------- ---------------------- ------------------------- -------------------------------- ------ ------ ---- ----------------------
  **Atrial fibrillation**                                                                                                                                      
  Total                     155 710              47 915   3.3                                              774                              94.5   8.2         1.42 (1.32 to 1.52)
  Women (age in years):                                                                                                                                        
   All                      73 656               24 532   3.0                                              491                              67.1   7.3         1.48 (1.36 to 1.62)
   \<50                     1 915                12 922   0.1                                              8                                16.8   0.5    69   2.96 (1.48 to 5.93)
   50-65                    9 502                6 387    1.5                                              72                               24.6   2.9    49   1.86 (1.48 to 2.35)
   \>65                     62 239               5 223    11.9                                             411                              25.8   16.0   25   1.26 (1.15 to 1.39)
  Men (age in years):                                                                                                                                          
   All                      82 054               23 383   3.3                                              283                              27.4   10.3        1.33 (1.19 to 1.50)
   \<50                     6 033                13 362   0.5                                              9                                5.9    1.5    70   3.11 (1.62 to 5.98)
   50-65                    21 064               6 296    3.3                                              65                               10.7   6.1    45   1.72 (1.35 to 2.19)
   \>65                     54 957               3 725    14.7                                             209                              10.8   19.4   24   1.24 (1.09 to 1.43)
  **Stroke**                                                                                                                                                   
  Total                     164 625              47 884   3.4                                              718                              94.8   7.6         1.33 (1.23 to 1.43)
  Women (age in years):                                                                                                                                        
   All                      81 772               24 500   3.3                                              457                              67.2   6.8         1.33 (1.22 to 1.46)
   \<50                     6 555                12 905   0.5                                              26                               16.7   1.7    67   3.11 (2.12 to 4.57)
   50-65                    14 163               6 362    2.2                                              90                               24.5   4.7    39   1.67 (1.36 to 2.06)
   \>65                     61 054               5 233    11.7                                             341                              26.1   15.3   11   1.14 (1.02 to 1.26)
  Men (age in years):                                                                                                                                          
   All                      82 853               23 384   3.5                                              261                              27.6   9.5         1.34 (1.19 to 1.51))
   \<50                     7 605                13 359   0.6                                              12                               5.9    2.0    72   3.61 (2.05 to 6.36)
   50-65                    23 861               6 285    3.8                                              68                               10.7   6.4    40   1.70 (1.34 to 2.15)
   \>65                     51 387               3740     13.7                                             181                              11.0   16.4   16   1.21 (1.05 to 1.40)

py=person years.

\*Rheumatoid arthritis as exposure.

†Adjusted for age, sex, and calendar year (age not included in age stratified model).

![**Fig 2** Rates of atrial fibrillation in general population and patients with rheumatoid arthritis](linj003076.f2_default){#fig2}

![**Fig 3** Rates of stroke in general population and patients with rheumatoid arthritis](linj003076.f3_default){#fig3}

Atrial fibrillation
-------------------

The overall incidence of atrial fibrillation was approximately 40% higher in rheumatoid arthritis patients than in the general population (age and sex matched event rates of 8.2 and 6.0 per 1000 person years). Women were at slightly higher relative risk than men, and the relative risk of atrial fibrillation was markedly increased in the youngest age groups; the absolute risk attributable to rheumatoid arthritis ranged from 25% in the oldest to 70% in the youngest age group.

The change in risk estimates after inclusion of baseline cardiovascular drug use and comorbidity in the analysis was negligible (table 3[](#tbl3){ref-type="table"}). The risk of atrial fibrillation associated with rheumatoid arthritis was somewhat reduced when all cardiovascular drug use and comorbidity was updated during follow-up (incidence rate ratio 1.24, 95% confidence interval 1.15 to 1.35). Interestingly, this effect was primarily driven by inclusion of loop diuretics (incidence rate ratio 1.25, 1.16 to 1.34, when these were included alone). To assess the influence of surveillance bias as a result of regular outpatient visits for rheumatoid arthritis, we did several sensitivity analyses. Firstly, we excluded cases of atrial fibrillation within the first month of the rheumatoid arthritis index (82 events) to reduce the effect of increased surveillance in relation to the diagnosis (consequent incidence rate ratio 1.39, 1.30 to 1.49). Secondly, we repeated analyses including only admissions with atrial fibrillation as the primary diagnosis (consequent incidence rate ratio 1.43, 1.29 to 1.59). Thirdly, we excluded users of vitamin K antagonists at baseline and during follow-up to diminish the contribution of patients with unreported prevalent atrial fibrillation (consequent incidence rate ratio 1.43, 1.33 to 1.53). Fourthly, we assessed risk of atrial fibrillation in patients with osteoarthritis (incidence rate ratio 1.17, 1.08 to 1.24), which was significantly lower compared with patients with rheumatoid arthritis, even though osteoarthritis is likely to lead to increased surveillance. Fifthly, we restricted analysis to follow-up of approximately half a million patients who were diagnosed as having cardiovascular disease as defined in table 1[](#tbl1){ref-type="table"} (consequent incidence rate ratio 1.43, 1.24 to 1.65).

###### 

 Atrial fibrillation and stroke: incidence rate ratio (95% CI) associated with rheumatoid arthritis

  Model                                                    Atrial fibrillation   Stroke
  -------------------------------------------------------- --------------------- ---------------------
  Adjusted for sex, age, and calendar year                 1.43 (1.33 to 1.53)   1.34 (1.24 to 1.44)
  Adjusted for above and socioeconomic status              1.42 (1.33 to 1.53)   1.33 (1.23 to 1.43)
  Adjusted for above and baseline cardiovascular drugs\*   1.41 (1.31 to 1.51)   1.32 (1.22 to 1.42)
  Adjusted for above and baseline comorbidity\*            1.41 (1.31 to 1.51)   1.32 (1.22 to 1.42)

\*As listed in table 1 (baseline characteristics).

Stroke
------

Age and sex matched stroke rates were 7.6 per 1000 person years in rheumatoid arthritis patients and 5.7 per 1000 person years in the general population, which corresponded to an overall increase in risk of 30%. Similar to the findings with atrial fibrillation, the relative risk was highest in the younger age groups, but with increasing absolute difference in incidence rates with increasing age up to 80 years and above (fig 3[](#fig3){ref-type="fig"}). By further analogy with the atrial fibrillation results, stroke risk varied minimally in our sensitivity analyses and when compared with that in patients with osteoarthritis.

Concerning contribution of atrial fibrillation to stroke risk, we found that updating atrial fibrillation diagnoses during follow-up slightly lowered the risk estimate for rheumatoid arthritis (incidence rate ratio 1.29, 1.20 to 1.39), which was consistent with the finding of no significant interaction between atrial fibrillation and rheumatoid arthritis (incidence rate ratio 0.92; P=0.49) and the limited follow-up in the group with both rheumatoid arthritis and atrial fibrillation.

Supplemental matched design study
---------------------------------

In general, baseline characteristics showed modestly increased frequencies of cardiovascular drug use and comorbidity in patients with rheumatoid arthritis (table 4[](#tbl4){ref-type="table"}). The results from Cox regression analyses corroborated the findings of the primary analysis (table 5[](#tbl5){ref-type="table"}). Successive inclusion of main groups of covariates only marginally changed the risk estimates for stroke, whereas a small decrease in risk of atrial fibrillation was observed when baseline cardiovascular drug use was included. This decrease was exclusively driven by the inclusion of loop diuretic use.

###### 

 Supplementary matched design analysis of risk of atrial fibrillation and stroke: baseline characteristics. Values are numbers (percentages) unless stated otherwise

  Characteristic                           General population (n=72 988)   Rheumatoid arthritis (n=18 247)   P value for difference\*
  ---------------------------------------- ------------------------------- --------------------------------- --------------------------
  Female sex                               50 904 (69.7)                   12 726 (69.7)                     NA
  Mean (SD) age (years):                                                                                     
   Women                                   58.9 (14.8)                     58.9 (14.8)                       NA
   Men                                     60.1 (13.6)                     60.1 (13.6)                       NA
  Comorbidity:                                                                                               
   Hypertension                            8 217 (11.3)                    2 272 (12.5)                      \<0.01
   Heart failure                           952 (1.3)                       436 (2.4)                         \<0.01
   Ischaemic heart disease                 4 139 (5.7)                     1 399 (7.7)                       \<0.01
   Hyperthyroid disease                    1 150 (1.6)                     388 (2.1)                         \<0.01
   Chronic obstructive pulmonary disease   2 131 (2.9)                     848 (4.6)                         \<0.01
   Heart surgery                           1 322 (1.8)                     439 (2.4)                         \<0.01
   Diabetes                                3 174 (4.3)                     967 (5.3)                         \<0.01
  Mean (SD) socioeconomic index            3.02 (1.41)                     2.98 (1.41)                       \<0.01
  Cardiovascular drugs:                                                                                      
   β blocker                               6 657 (9.1)                     1 895 (10.4)                      \<0.01
   Cholesterol lowering drug               5 955 (8.2)                     1 544 (8.5)                       0.16
   ACEI/ARB                                9 029 (12.4)                    2 581 (14.1)                      \<0.01
   Calcium channel blocker                 4 764 (6.5)                     1 404 (7.7)                       \<0.01
   Thiazide diuretic                       7 982 (10.9)                    2 595 (14.2)                      \<0.01
   Loop diuretic                           3 801 (5.2)                     1 843 (10.1)                      \<0.01
   Spironolactone                          745 (1.0)                       344 (1.9)                         \<0.01
   Vitamin K antagonist                    697 (1.0)                       444 (2.4)                         \<0.01
   Platelet inhibitor                      6 013 (8.2)                     1 864 (10.2)                      \<0.01

ACEI=angiotensin converting enzyme inhibitor; ARB=angiotensin 2 receptor blocker; NA=not applicable.

\*Unadjusted conditional (matched set) logistic regression.

###### 

 Supplementary matched design analysis of risk of atrial fibrillation and stroke: hazard ratio (95% CI) associated with rheumatoid arthritis

  Model                                                    Atrial fibrillation   Stroke
  -------------------------------------------------------- --------------------- ---------------------
  Adjusted for calendar year (sex and age matched)         1.48 (1.36 to 1.62)   1.41 (1.28 to 1.55)
  Adjusted for above and socioeconomic status              1.47 (1.35 to 1.61)   1.40 (1.28 to 1.54)
  Adjusted for above and baseline cardiovascular drugs\*   1.40 (1.28 to 1.54)   1.39 (1.26 to 1.54)
  Adjusted for above and baseline morbidity\*              1.39 (1.27 to 1.53)   1.38 (1.26 to 1.52)

\*As listed in table 4 (baseline characteristics).

Discussion
==========

This study examined the incidence of atrial fibrillation and stroke in a Danish nationwide register based cohort including more than 18 000 patients with rheumatoid arthritis who were followed for up to 13 years. The incidence of atrial fibrillation was found to be 40% higher in rheumatoid arthritis patients than in the general population, and the risk of stroke in rheumatoid arthritis patients was roughly 30% higher. For both atrial fibrillation and stroke, we saw remarkable threefold increases in the relative risks in patients with rheumatoid arthritis younger than 50, as also indicated by the high proportion of the risk that was attributable to rheumatoid arthritis in young compared with older patients. Nonetheless, the absolute differences in rates of atrial fibrillation and stroke between people with and without rheumatoid arthritis were highest in the oldest patients.

Comparison with other studies
-----------------------------

To our knowledge, the incidence of atrial fibrillation has not previously been examined in a large rheumatoid arthritis population, and only a very limited number of small clinical studies have examined the occurrence of arrhythmias in these patients, with no reports on atrial fibrillation.[@ref26] [@ref27] [@ref28] Although the increased incidence of atrial fibrillation in patients with rheumatoid arthritis is a novel finding that must be tested in other cohorts, several lines of evidence support this result. Firstly, mounting evidence indicates that heart failure is more prevalent in rheumatoid arthritis compared with controls.[@ref13] [@ref14] As heart failure is strongly associated with atrial fibrillation (and vice versa), this observation may explain some of the increased risk of atrial fibrillation, as also suggested by the fact that in our study estimates atrial fibrillation risk were primarily affected by time varying confounder adjustment for loop diuretics, which are routinely used for heart failure. Secondly, patients with rheumatoid arthritis show increased arterial stiffness, which is a risk factor for heart failure and atrial fibrillation.[@ref29] [@ref30] [@ref31] Thirdly, recent reports have also suggested use of glucocorticoids and non-steroidal anti-inflammatory drugs as a risk factor for atrial fibrillation; however, although such associations could explain part of the increased risk of atrial fibrillation in rheumatoid arthritis, these studies were cross sectional in their design and subject to confounding by indication (that is, the drugs were prescribed for diseases associated with atrial fibrillation including rheumatoid arthritis and chronic obstructive pulmonary disease).[@ref32] [@ref33] Fourthly, inflammation itself has been proposed as playing a role in development of atrial fibrillation, and increased circulating concentrations of inflammatory markers such as C reactive protein have been associated with atrial fibrillation and lower rates of successful cardioversion.[@ref15] [@ref34] [@ref35] Increased P wave dispersion in electrocardiography, which is considered to be a predictor of atrial fibrillation, also occurs more frequently in people with rheumatoid arthritis and seems to be highly correlated with the level of systemic inflammation.[@ref36] [@ref37] The sum of current evidence therefore clearly suggests that chronic inflammation contributes to the increased risk of atrial fibrillation in patients with rheumatoid arthritis.

In contrast to consistent data indicating an increased risk of myocardial infarction in rheumatoid arthritis, reports on the rheumatoid arthritis related risk of stroke are conflicting. One recent meta-analysis concluded that the risk of myocardial infarction, but not stroke, was significantly increased in patients with rheumatoid arthritis, whereas another found a twofold increased risk of both stroke and myocardial infarction.[@ref2] [@ref3] The two most recent large cohort studies in this area of research also had contradictory conclusions.[@ref6] [@ref10] As their main difference was in the duration of rheumatoid arthritis at cohort entry, which probably also reflected differences in the rheumatoid arthritis treatment strategy (with more aggressive treatment being the mainstay of modern management), the risk of stroke might be more dependent on the duration of rheumatoid arthritis and its treatment than is the case for the risk of myocardial infarction. We were not able to specifically explore this hypothesis in our study, not least because data on duration of symptoms before diagnosis of rheumatoid arthritis were lacking. However, the marked age dependent relative risk of stroke attributable to rheumatoid arthritis may offer another explanation for the inconsistent results in previous studies, as the differences in stroke risk could be caused by variations in age distributions in the rheumatoid arthritis populations studied.[@ref2] [@ref3] [@ref4] [@ref5] [@ref6] [@ref7] [@ref8] [@ref9] [@ref10] To what extent the increased risk of atrial fibrillation contributed to the increased risk of stroke in rheumatoid arthritis patients was not clear owing to a limited follow-up in these cases, but no major effect modification was noted, which indicated that rheumatoid arthritis was a risk factor for stroke beyond the increased risk of atrial fibrillation.

The increased risk of stroke in patients with rheumatoid arthritis is most likely to represent a multifactorial process in which accelerated inflammation driven atherothrombosis, a higher prevalence of classical risk factors, adverse effects of rheumatoid arthritis treatment, and increased risk of atrial fibrillation play important roles.[@ref12] [@ref30] [@ref38] [@ref39] At the time of diagnosis, patients with rheumatoid arthritis already have an increased prevalence of carotid plaques compared with controls.[@ref40] [@ref41] Also, endothelial dysfunction and increased vascular stiffness, which are predictors of atherosclerotic disease including stroke, are seen in these patients and may improve after anti-inflammatory treatment, although the very same treatment may augment the cardiovascular risk through other pathways (for example, non-steroidal anti-inflammatory drugs, glucocorticoids, and cytotoxic disease modifying antirheumatic drugs).[@ref30] [@ref38] [@ref42] [@ref43]

Clinical implications
---------------------

In the recent years, the care of patients with rheumatoid arthritis has been extended to cover the increased comorbidity, especially that due to cardiovascular disease. Newly developed guidelines recommend annual screening for cardiovascular risk factors in patients with rheumatoid arthritis, to counter the reported increased risk of, for example, acute myocardial infarction and stroke.[@ref38] As no evidence has been available on the risk of atrial fibrillation, the focus has primarily been on standard primary prevention of hard end points by traditional risk score assessment. Overall, our findings corresponded to one new case of atrial fibrillation per 12 rheumatoid arthritis patients followed for 10 years after diagnosis. Given the augmented risk of atrial fibrillation (which is often asymptomatic) and the ample opportunity for diagnosis of arrhythmia at the recommended annual screening appointments, we suggest that the clinical focus should here include screening for atrial fibrillation, not least in light of the relative easiness of such screening, the risk of stroke with subsequent disability and societal burden, and the powerful effect of anticoagulation treatment. Moreover, these findings may indicate that rheumatoid arthritis can add to future risk stratification scores for stroke in patients with atrial fibrillation and lower the threshold for anticoagulation. As inflammation is likely to play a significant role in the pathogenesis of atrial fibrillation and stroke, this study also underlines the importance of rigorous control of inflammation with disease modifying antirheumatic drugs, not only for the management of joint symptoms but also to reduce the need for drugs with potential adverse cardiovascular effects and, ultimately, to diminish the inflammation driven atherothrombotic process.

Strengths and weaknesses
------------------------

Although our results were strengthened by a high number of unselected patients with rheumatoid arthritis, an untruncated age span, and a contemporary study cohort, several important limitations should be considered when evaluating the findings. Given the register based approach, people were identified as having rheumatoid arthritis by dispensed prescriptions for disease modifying antirheumatic drugs and recorded diagnoses rather than by use of formal clinical criteria. Therefore, cases of rheumatoid arthritis who were not treated with such drugs as well as cases who did not attend a hospital clinic at any time during the study were excluded. These cases may have a less active disease and hence a lower risk of comorbidity, but they probably represent a small minority of patients, considering the national treatment guidelines in the study period. Conversely, the risk could be underestimated by examining treated patients only, especially as inflammation is likely to be an important contributor to both outcomes. Of note, the incidence of rheumatoid arthritis in this study corresponded closely to those in previous Danish clinic based incidence studies.[@ref44] The identification of study end points relied on diagnoses from hospital admissions. Whereas stroke usually leads to hospital admission (and thus capture in the registers), this is not always the case for atrial fibrillation. However, the sensitivity of the diagnosis of atrial fibrillation in the national patient register was previously found to be 88%, and the specificity was 88-99%.[@ref19] [@ref20] [@ref21] Also, the incidence of atrial fibrillation identified in this study was similar to the findings in a large contemporary European population based study.[@ref45]

Surveillance bias due to more frequent examinations in patients with rheumatoid arthritis may have exaggerated the risk of atrial fibrillation related to rheumatoid arthritis and was therefore assessed in several sensitivity analyses. Importantly, when analysis was restricted to cases in which atrial fibrillation was the primary cause of admittance, which are less likely to be differential with regard to rheumatoid arthritis status as such cases are most often due to sudden onset of significant symptoms, the results were not affected. Also, findings were consistent in people with previous cardiovascular disease, among whom both rheumatoid arthritis patients and controls would arguably have similar level of surveillance for the diagnosis of atrial fibrillation. Moreover, until recently,[@ref38] cardiovascular examinations including pulse assessment and cardiac auscultation were usually restricted to initial evaluation at diagnosis of rheumatoid arthritis, but exclusion of end points within the first month after diagnosis had no effect on our findings.

Another important consideration was whether our adjustments for confounding factors were adequate. In general, we controlled for age and calendar year by including these as additional time scales and by presenting age stratified results. In addition, the main results were similar in age and sex matched models in which length of follow-up was similar in the two groups, averaging five years. We lacked information on several important cardiovascular risk factors, and as patients with rheumatoid arthritis may have a higher prevalence of smoking, dyslipidaemia, and reduced physical exercise, availability of such information could change the risk estimates, although some of this unmeasured confounding was probably controlled for by inclusion of several cardiovascular drugs and comorbidities in the analyses

Moreover, most of these confounders, such as heart failure and dyslipidaemia, reduced physical exercise, and adverse effects of antirheumatoid arthritis drugs are inherently prevalent in rheumatoid arthritis and to some extent represent intermediaries in the pathway from rheumatoid arthritis to stroke or atrial fibrillation. Consequently, their inclusion in our analyses would tend to underestimate the risk of atrial fibrillation and stroke in the average patient with rheumatoid arthritis.

Overall, these potential sources of bias and confounding were inherent to the observational nature of our study and, despite our attempts to identify their contributions to the results, we cannot exclude the effects of additional unmeasured factors.

Conclusions
-----------

This study of more than 18 000 patients with rheumatoid arthritis found a 40% increase in risk of atrial fibrillation and a 30% increase in the risk of stroke. The augmented risk of stroke in rheumatoid arthritis adds significantly to existing evidence, and the novel finding of an increased incidence of atrial fibrillation suggests that this arrhythmia is relevant in cardiovascular risk assessment of these patients.

### What is already known on this topic

1.  Patients with rheumatoid arthritis have increased risk of myocardial infarction and cardiovascular death

2.  The incidence of atrial fibrillation in rheumatoid arthritis is unknown

3.  Data on the risk of stroke in rheumatoid arthritis are contradictory, and the role of atrial fibrillation in this context is unknown

### What this study adds

1.  Patients with rheumatoid arthritis had a 40% higher risk of atrial fibrillation compared with the general population

2.  The risk of stroke was increased by 30% in rheumatoid arthritis compared with the general population

3.  The study suggests that increased focus on atrial fibrillation in the cardiovascular risk assessment of patients with rheumatoid arthritis is warranted
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